On Friday, an advisory committee to the Food and Drug Administration is reviewing aducanumab, the Alzheimer’s disease treatment developed by Biogen. We’ll be monitoring the meeting and posting analysis throughout the day. Updates will be posted in reverse chronological order.
As a reminder of why this meeting matters: If approved, aducanumab would become the first new Alzheimer’s therapy in nearly two decades — and the first drug to reduce cognitive decline by targeting and eliminating clumps of a toxic protein called beta amyloid that are believed to destroy the brain.
For Biogen, of course, the drug would be a blockbuster.